Clinical Trial Update: Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) [Phase 3]

View source ↗

Summary

Phase 3 trial (V501-041) completed, evaluating the prevention of human papillomavirus infection in Chinese women aged 20-45; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HPV Infections | Phase 3 | Status: COMPLETED | Results posted: 2017-10-12